drugset / Trial / NCT01262352
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
Phase 2
Completed
21 enrolled
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effect of ivacaftor (VX-770) on lung clearance index (LCI) in subjects aged 6 years and older with cystic fibrosis (CF) who have the G551D-CFTR mutation on at least 1 allele.
Timeline
- Start
- 2011-01
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivacaftor | Other / unclassified | 150 mg | Oral |